Nov 11,2020

Practicing 'neurobics' before surgery found to reduce risk for postoperative delirium

Playing brain games during the lead up to surgery can prevent postoperative delirium in older adults, according to new research from the Ohio State University Wexner Medical Center. These brain games are called "neurobics," and they're intended to create new neural pathways and increase cognition, which could lead to better postoperative outcomes. Gamification is becoming an increasingly popular trend to address cognitive health. Researchers have also looked at how brain games can help breast cancer patients improve their cognitive function after undergoing chemotherapy.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 19,2020

New DarioHealth Study Shows Increased Digital Therapeutics Engagement Leads to Marked Reduction in Blood Glucose, Lower High Readings among Type 2 Diabetic Seniors

DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (DTS), which showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario's digital therapeutics platform (Dario DTx). The study was based on retrospective data analysis of a cohort of Dario members with non-insulin-dependent type 2 diabetes, evaluated for a period of 12-months continuous Dario DTx use. The observed results showed that the positive clinical outcomes for adults over the age of 65 using the Dario platform were comparable, and in some cases more favorable, than those of younger adults (<65 age).

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Dec 11,2020

Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O

Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, “Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder”, published in the peer-reviewed Journal of Medical Economics, concluded that reSET-O plus treatment-as-usual (TAU) was cost effective versus TAU alone, and economically dominant when TAU included contingency management (CM), with both scenarios producing a 16.3% absolute increase in retention in therapy vs TAU.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Dec 16,2020

Simulation model: Big Health's Sleepio drives greater cost savings than group CBT or drug therapy

The research was funded by Big Health, and conducted by researchers from Johns Hopkins, the University of California, San Francisco, and the digital health company. The mathematical simulation model found that, compared to other insomnia interventions like group cognitive behavioral therapy or pharmacotherapy, digital CBT delivered via Big Health's Sleepio was more cost-effective due to lower expenditures. Compared to no insomnia treatment, the model indicated a net monetary benefit of $681.06 per individual receiving Sleepio over six months.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 12,2019

Akili's video game therapy linked to reduced cognitive impairments in patients with depression

A video game-like digital therapy may be key to helping reduce cognitive impairments in adults living with major depressive disorder (MDD). Results out of a new study conducted by Akili interactive found that patients using the company’s AKL-T03 significantly improved their sustained attention compared to their peers in the control group. The yet-to-be published research also found that the tool showed improvements in cognition, depression and quality of life; however, this wasn’t a significant difference from the control group.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 15,2019

DarioHealth® Clinical Study Data Highlights the Material Benefit Digital Interventions Have on Glycemic Control in Users with Diabetes

DarioHealth, a leading global, digital therapeutics company, presented new clinical data yesterday at the 19th Annual Diabetes Technology Meeting ("DTM") conference in Bethesda, Maryland, which showed remarkable improvements in average blood glucose levels (BGavg) and in-range measurements in patients with diabetes using Dario's digital therapeutics platform and dedicated one-on-one personal health coaching. The Dario study was based on an analysis of clinical data of 162 Dario users. The results showed that 51 users considered "high risk" (started with BGavg >180 mg/dL) increased their % in-range measurements by 38% (48% vs. 35%) and reduced their BGavg by 14% (192±39 vs. 224±38) on average.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Nov 22,2019

Roundup: 16 digital health studies, pilots and reviews from AHA 2019

From mobile ECGs to tele-rehabilitation to defibrillator delivery drones, a range of new data was on display at the American Heart Association Scientific Sessions 2019.

CLINICAL STUDY

#connected device

#rpm

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 01,2019

Study: Many people with asthma or COPD experience nighttime symptoms

Propeller presented data on rescue inhaler use, collected with Propeller’s digital health platform, that reveals new insights about nighttime symptoms of asthma and COPD. The research, conducted in partnership with Children’s Hospital Colorado, is the first to use digital health data to study how patients experience nocturnal symptoms of asthma and COPD, rather than relying on patient recall or manual tracking. To study nighttime symptoms, Propeller analyzed rescue inhaler use data from 1,930 asthma and 591 COPD patients over the course of 180 days. The study found that the prevalence of nighttime symptoms was high for patients with COPD and asthma. During the six months of observation, patients experienced a median of five nighttime events for asthma and 16 for COPD.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 07,2019

Study: Proteus' digital pill system accurate, improved adherence among California TB patients

Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California. Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home were more likely to keep up with their doses, and across the board preferred the system to gold-standard adherence programs requiring medication to be confirmed by an in-person provider.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 07,2019

Physitrack - Independent Scientific Study Proves Significant Positive Impact on Patient Journey

The world-leading Department of Physiotherapy of the University of Melbourne, Australia, has published a multi-year, independent scientific study of exercise adherence among patients recovering from orthopaedic injuries in the American Journal of Physical Medicine & Rehabilitation. The results of the study, the first independent one conducted at such scale, suggest that the use of Physitrack has a positive impact on the effectiveness of physiotherapy treatment as well as the quality and speed of patient recovery, which in turn reduce direct and indirect costs of rehabilitation.

CLINICAL STUDY

#pdt

#telehealth

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY